IZASKUN
ZEBERIO ETXETXIPIA
Investigadora hasta 2022
Publicaciones (13) Publicaciones de IZASKUN ZEBERIO ETXETXIPIA
2023
-
Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma
Annals of Hematology, Vol. 102, Núm. 2, pp. 429-437
2022
-
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
International Journal of Hematology, Vol. 116, Núm. 3, pp. 381-392
2020
-
Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease
Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 2, pp. 323-332
-
Identification of recurrent mutations in the microrna‐binding sites of b‐cell lymphoma‐ associated genes in follicular lymphoma
International Journal of Molecular Sciences, Vol. 21, Núm. 22, pp. 1-12
-
Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain
Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 8, pp. 1534-1542
2017
-
Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation
Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 1, pp. 67-74
-
Lehen mailako arretaren eta hematologiako kontsultaren arteko deribazio- eta kudeaketa-irizpideak
Osagaiz: osasun-zientzien aldizkaria, Vol. 1, Núm. 2, pp. 43-51
2015
-
Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 6, pp. 971-983
-
Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT
Bone Marrow Transplantation, Vol. 50, Núm. 3, pp. 438-443
-
Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant
Leukemia and Lymphoma, Vol. 56, Núm. 3, pp. 663-670
2014
-
A Phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with BCell lymphoid malignancies: Favorably durable event-free survival in chemosensitive patients
Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 3, pp. 354-360
2013
-
Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation
Nature Medicine, Vol. 19, Núm. 3, pp. 372-377
2003
-
Evaluation of the factor V HR2 haplotype as a risk factor for ischemic cerebrovascular disease
Haematologica, Vol. 88, Núm. 2, pp. 236-237